Grandbrothers
The FDA is evaluating reports that GLP-1 drugs such as Wegovy, Ozempic and Mounjaro may be associated with hair loss, suicidal thoughts and aspiration issues in certain users.
According to the FDA’s adverse events web page, the agency is “evaluating the need for regulatory action” in regards to reports involving Adlyxin, Byetta, Bydureon, Mounjaro, Ozempic, Rybelsus, Saxenda, Soliqua, Trulicity, Victoza, Wegovy, Xultophy and Zepbound. The medications are marketed by companies such as Eli Lilly (NYSE:LLY), Novo Nordisk (NVO), AstraZeneca (NASDAQ:AZN) and Sanofi (NASDAQ:SNY).
The website also notes that a report does not mean the suspected drug actually caused the reaction.
Earlier Friday, a scientific analysis published by Nature Medicine found that semaglutide drugs were not associated an increased risk of suicidal thoughts. Semaglutide is the main ingredient in Novo Nordisk’s Wegovy, Ozempic and Rybelsus.
More on AstraZeneca, Eli Lilly, etc.
Source link
